FORGOTTEN HISTORY: 4 | History Defined

Where McKesson Stands With Analysts

Over the past 3 months, 5 analysts have published their opinion on McKesson (NYSE:MCK) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · Jun 7, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022

Upgrades

Benzinga · Jun 7, 2022

$1000 Invested In McKesson 15 Years Ago Would Be Worth This Much

McKesson (NYSE:MCK) has outperformed the market over the past 15 years by 4.74% on an annualized basis producing an average annual return of 11.75%. Currently, McKesson has a market capitalization of $46.98 billion.

Benzinga · Jun 1, 2022

4 Analysts Have This to Say About McKesson

McKesson (NYSE:MCK) has observed the following analyst ratings within the last quarter:

Benzinga · May 11, 2022

Here's How Much You Would Have Made Owning McKesson Stock In The Last 5 Years

McKesson (NYSE:MCK) has outperformed the market over the past 5 years by 6.7% on an annualized basis producing an average annual return of 17.83%. Currently, McKesson has a market capitalization of $49.19 billion.

Benzinga · May 9, 2022

Why McKesson Shares Are Jumping Today

McKesson Corp (NYSE:MCK) reported Q4 FY22 adjusted EPS of $5.83, +15% Y/Y, and missing the consensus of $6.04. Revenues increased 12% Y/Y to $66.10 billion, surpassing the consensus of $63.61 billion. U.S. Pharmaceutical segment's Q4 FY22 revenues were $53.67 billion, +14%, driven by an increased volume of specialty products, including higher volumes…

Benzinga · May 6, 2022

McKesson: Q4 Earnings Insights

McKesson (NYSE:MCK) reported its Q4 earnings results on Thursday, May 5, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings McKesson missed estimated earnings by 3.48%, reporting an EPS of $5.83 versus an estimate of $6.04.

Benzinga · May 5, 2022

Washington, Drug Distributors Reach $518M Settlement For Opioid Claims

Washington has reached a $518 million settlement with drug distributors McKesson Corporation (NYSE:MCK), AmerisourceBergen Corp (NYSE:ABC), and Cardinal Health Inc (NYSE:CAH) to resolve opioid-related claims. Washington opted out of a $26 billion nationwide opioid settlement involving the three drug distributors and Johnson & Johnson (NYSE:JNJ). Reuters writes that it would…

Benzinga · May 3, 2022

San Francisco To Start Opioid Epidemic Trial Against Teva, Walgreen: Reuters

San Francisco will start a trial against Walgreens Boots Alliance Inc (NASDAQ:WBA) and three other companies accused of fueling an opioid crisis in the city. San Francisco has alleged that Walgreens, Teva Pharmaceutical Industries Ltd (NYSE:TEVA), AbbVie Inc's (NYSE:ABBV) Allergan unit, and Teva-owned Anda Inc created a "public nuisance" by flooding the city with prescription opioids and failing…

Benzinga · Apr 25, 2022

President Biden To Outline Strategy To Tackle Drug Addiction, Overdose: Reuters

U.S. President Joe Biden will reveal a new strategy today for dealing with drug addiction and overdoses to expand access to medications for opioid overdoses, increase funding for law enforcement, and expand sanctions against traffickers. According to U.S. Centers For Disease Control And Prevention Data, the U.S. opioid crisis fueled more than…

Benzinga · Apr 21, 2022